Mesoblast's Phase 2 Trial Results In Chronic Low Back Pain Presented at North American Spine Society Annual Meeting

Melbourne, AUSTRALIA


NEW YORK and MELBOURNE, Australia, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Mesoblast's Phase 2 trial results in degenerative disc disease were presented today at the North American Spine Society (NASS) Annual Meeting, the premier global conference for spine disease professionals. The key outcome of the trial was that a single injection of Mesoblast's proprietary allogeneic Mesenchymal Precursor Cell (MPC) product resulted in sustained improvements in pain and function at 12 months.